These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29933241)

  • 1. Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation.
    Prasolov AV; Kolbin AS; Balykina YE
    Value Health Reg Issues; 2018 Sep; 16():39-45. PubMed ID: 29933241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Policy in the Russian Federation.
    Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
    Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policy reform in the Russian Federation.
    Rudisill C; Vandoros S; Antoun JG
    J Health Polit Policy Law; 2014 Jun; 39(3):691-705. PubMed ID: 24603082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The French medecine pricing committee and the medicine economic policy: Rules and competences].
    Giorgi D
    Ann Pharm Fr; 2017 Sep; 75(5):359-372. PubMed ID: 28522031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Data Sources for Medicine Price Studies.
    Vogler S; Schneider P
    Int J Technol Assess Health Care; 2019 Jan; 35(2):106-115. PubMed ID: 30922418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Price of medications: the actual system must be seen again].
    Mayencourt J
    Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 19. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.